Celltrion Pharm: Q1 2026 Revenue 132.1B Won, Share Buyback & Dividend

Q1 2026 revenue 132.1B won, operating profit 12.9B won, net profit 8.8B won, EPS 199 won
26th AGM approved cash dividend 200 won/share and stock dividend 2%, resolved disposal and cancellation of treasury shares
Key products: Godex (liver) 17.7B won, biosimilars (Remsima etc.) 21.3B won
R&D expenditure 3.94B won (2.99% of revenue), 63 R&D personnel
License agreement with MPP for generic Paxlovid (95 developing countries, royalty contingent)
Related party transactions: sales to parent Celltrion 30.1B won, purchases 28.5B won
No material litigation or contingencies; sound financial position (debt ratio 43.4%)